AI has moved from concept to execution in drug discovery, but turning algorithms into actionable insights requires deep scientific alignment and cross-functional integration. This session brings together leaders from pharmaceutical and techbio companies to discuss how AI is redefining discovery, validation, and collaboration models across the biopharma ecosystem. Panelists will explore what it truly takes to make AI deliver measurable impact - building high-quality datasets, designing interpretable generative models, and translating predictions into experimentally validated outcomes. The conversation will also address how pharma and AI-native companies can collaborate more effectively, balancing innovation speed, data governance, and scientific credibility.